Announcement on Resolutions of the 4th General Meeting in 2025
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
The meeting was held to discuss important matters, including changes to the company's business scope and amendments to the articles of association. All proposed resolutions were approved by the shareholders present at the meeting, with no dissenting votes recorded. The filing confirms that the meeting was conducted in accordance with relevant laws and regulations, ensuring the validity of the proceedings.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shaanxi Kanghui Pharmaceutical Co., Ltd. on 6ix
Earlier from Shaanxi Kanghui Pharmaceutical
- Notice on Convening the 4th Extraordinary General Meeting in 2025
- Announcement on Providing Guarantee for Holding Subsidiary
- Announcement on Applying for Arbitration Regarding Performance Compensation Matters and Accumulated Litigation
- Announcement on Increasing the Estimated Amount for Daily Related Party Transactions in 2025
- Announcement on Resolutions of the 3rd General Meeting in 2025
Later from Shaanxi Kanghui Pharmaceutical
- Announcement on the Pledge of Some Shares by the Person Acting in Concert of Shareholders with Over 5% Shares
- Announcement on Changing Business Scope and Completing Industrial and Commercial Change Registration
- Announcement on Occurrence of Daily Related Party Transactions in 2025 and Estimated Daily Related Party Transactions in 2026
- Announcement on Progress in Providing Guarantee for Holding Subsidiary
- Earnings Preannouncement for 2025
Follow Shaanxi Kanghui Pharmaceutical into a list and get an email when it puts out news.
Follow Shaanxi Kanghui Pharmaceutical